These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Olfactory distortions in the general population. Olofsson JK; Ekesten F; Nordin S Sci Rep; 2022 Jun; 12(1):9776. PubMed ID: 35697904 [TBL] [Abstract][Full Text] [Related]
8. Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database. Dumont A; Dolladille C; de Boysson H; Alexandre J; Nguyen A; Deshayes S; Aouba A Autoimmun Rev; 2022 Sep; 21(9):103157. PubMed ID: 35902047 [TBL] [Abstract][Full Text] [Related]
9. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase. Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242 [TBL] [Abstract][Full Text] [Related]
10. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559 [TBL] [Abstract][Full Text] [Related]
11. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database. Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709 [TBL] [Abstract][Full Text] [Related]
12. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase. Perino J; Mottal N; Bohbot Y; Servant V; Berroneau A; Poustis P; Fenaux P; Laribi K; Charbonnier A; Bilion E; Calmettes C; Bégaud B; Pigneux A; Milpied N; Miremont-Salamé G; Théophile H; Dimicoli-Salazar S Br J Clin Pharmacol; 2020 May; 86(5):991-998. PubMed ID: 31912911 [TBL] [Abstract][Full Text] [Related]
13. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020. Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058 [TBL] [Abstract][Full Text] [Related]
14. Modified Olfactory Training Is an Effective Treatment Method for COVID-19 Induced Parosmia. Altundag A; Yilmaz E; Kesimli MC Laryngoscope; 2022 Jul; 132(7):1433-1438. PubMed ID: 35257391 [TBL] [Abstract][Full Text] [Related]
15. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase Chandler RE; Juhlin K; Fransson J; Caster O; Edwards IR; Norén GN Drug Saf; 2017 Jan; 40(1):81-90. PubMed ID: 27638661 [TBL] [Abstract][Full Text] [Related]
16. Clinical Features of Parosmia Associated With COVID-19 Infection. Lerner DK; Garvey KL; Arrighi-Allisan AE; Filimonov A; Filip P; Shah J; Tweel B; Del Signore A; Schaberg M; Colley P; Govindaraj S; Iloreta AM Laryngoscope; 2022 Mar; 132(3):633-639. PubMed ID: 34870334 [TBL] [Abstract][Full Text] [Related]
17. A study on the prognostic significance of qualitative olfactory dysfunction. Reden J; Maroldt H; Fritz A; Zahnert T; Hummel T Eur Arch Otorhinolaryngol; 2007 Feb; 264(2):139-44. PubMed ID: 17006637 [TBL] [Abstract][Full Text] [Related]
18. Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase. Noseda R; Ripellino P; Ghidossi S; Bertoli R; Ceschi A Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579259 [TBL] [Abstract][Full Text] [Related]
19. Qualitative smell/taste disorders as sequelae of acute COVID-19. Ercoli T; Masala C; Pinna I; Orofino G; Solla P; Rocchi L; Defazio G Neurol Sci; 2021 Dec; 42(12):4921-4926. PubMed ID: 34557966 [TBL] [Abstract][Full Text] [Related]
20. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]